Proteomic analysis
Proteomic approaches have enabled the identification of thousands of differentially expressed proteins in complex mixtures and also ushered the capability of discriminating disease subtypes/aggresiveness that are not recognised by traditional criteria. Thus, it offers a platform for the identification and quantification of proteins and may uncover new therapeutic targets. Translation of protein biomarkers in FDA approved diagnostic can be carried out at BMSF.
Some examples of what we can do include:
- Quantitative analysis (iTRAQ, comparative proteomics, MRM)
- Protein modification determination
- Separations (pre-fractionation, SDS-PAGE, 2D-gels)
- Analysis of tryptic digests, gel-fractions and peptides in biological extracts
- Determine pancreatic polypeptide levels in human plasma
- Mass determinations of intact proteins/glysosylations level estimation
- Top/Middle Down protein analysis by ECD, ETD, and IRMPD
- Development of phosphorylation assays used to investigate cell-signalling
- Phosphopeptide analysis by TiO2, IMAC and anti-phosphotyrosine enrichment
- Low mass peptide/protein (<25kDa) enrichment from complex proteomes
- nanoLC-MS/MS protein digest analysis (LysC, AspN, Chyotrypsin etc)
- De novo sequencing of peptides and small proteins
- Mascot, SEQUEST, MaxQuant or PEAKS searches for protein identification
- iTRAQ analysis and quantitation
- SILAC analysis and quantitation
- High resolution UPLC label free protein quantification
- Static nanospray of peptides and proteins including antibodies
- MALDI-ToF tissue imaging
- Interpretation of results
- SWATH (data independent acquisition)